Targeting Myofibroblasts as a Treatment Modality for Dupuytren Disease
Currently, no treatment corrects the contractile nature of Dupuytren myofibroblasts (DMFs) or prevents recurrence following surgery. Antifibrotic and proadipogenic growth factors are released when adipose-derived stem cells (ASCs) are cultured with platelet-rich plasma (PRP), a platelet concentration from whole blood. Reprograming myofibroblasts into adipocytes via growth factors is proposed as a powerful potential tool to target fibrosis. We aimed to assess whether the combination of ASCs and PRP reprograms DMFs into adipocytes in vitro and alters their contractile nature in vivo.
Source: The Journal of Hand Surgery - Category: Surgery Authors: Mary E. Ziegler, Andres Staben, Melinda Lem, Jason Pham, Leonardo Alaniz, Faris F. Halaseh, Sabine Obagi, Amber Leis, Alan D. Widgerow Tags: Editor's Choice Source Type: research